BioIVT

With nearly three decades at XenoTech and BioIVT, Dr. Brian Ogilvie has played a key role in advancing drug development. But what truly drives him? In our newest #MeetTheScientist interview, we learn one of his biggest passions is tackling rare diseases and unmet medical needs. Rare diseases are "individually rare but collectively common," affecting 25–30 million people in the U.S. With over 7,000 rare diseases, many remain unknown or undiagnosed. Brian finds particular purpose consulting on drug candidates designed to address unmet medical needs. Read more on Brian’s journey: https://hubs.ly/Q03c44s70 #ADME #DrugInteractions #RareDiseases #DrugDevelopment

🔬 Liquid biopsy research is transforming how we detect, diagnose, and treat cancer, including lung, breast, colon or even kidney cancer. But to fully unlock its potential, we must ensure assays deliver accurate, reproducible, and relevant results for the patients who need them most. What are the key factors in developing high-quality, high-value assays? And how do you select a biospecimen provider who upholds the highest standards? Explore the latest insights in our blog: https://lnkd.in/eKXww24C #LiquidBiopsy #CancerResearch #KidneyCancer #Biospecimens #Diagnostics

Kristin Knickerbocker, Courtney Noah, Kyle McIntyre and Samrina Lamichhane are ready at the #Alzheimers & #Parkinsons #DrugDevelopment Summit to help you find the right specimens for your research. As the world’s largest private repository of human #cerebrospinal fluid, we provide unparalleled access to high quality, ethically sourced #neuroscience #biospecimens. And make sure to catch our #ScientificPoster this evening entitled “Investigating the Impact of Age, Race/Ethnicity, and Gender on Alzheimer's and Parkinson’s Biomarkers” exploring the variability of #biomarkers based on demographic factors. #Neurodegenerative #NeuroscienceResearch #BioIVTNeuroExcellence #CenterforNeuroExcellence

Cell and gene therapies are transforming medicine, offering groundbreaking treatments for diseases once thought untreatable. A critical driver of this revolution? Patient-derived immune cells. In the latest Bio-Europe Spring magazine, Cathie G. Miller, PhD explores how these immune cells are bridging the gap between lab research and clinical application, driving advancements in autologous therapies, personalized treatment selection, and immune system modulation. https://hubs.ly/Q03ck2BF0 Samedan Ltd European Biopharmaceutical Review (EBR) #CellTherapy #GeneTherapy #AdvancedTherapies

Visit Lisa Kretzschmar, Courtney Cambouris and Lauren Styles at #AdvancedTherapies UK booth #27 to discuss securing a trusted RUO + GMP provider for cellular starting materials and more! And don’t miss poster #63 analyzing the impact of temperature conditions on cell stability in #leukopaks during shipping. Logistics plays a critical role in the quality of #biospecimens by the time they reach the hands of researchers, which can greatly impact research and development outcomes. Stop by to learn more! Advanced Therapies #ATMPs #CellandGeneTherapy #CellTherapy #GeneTherapy

It’s shaping up to be a great Society of Toxicology (SOT) Meeting & #ToxExpo! Our team is ready at booth #835 to discuss how we can help you access superior #biospecimens, achieve research results that you can trust, and meet regulatory expectations. And make sure you don’t miss the presentation by Sara Geriesh with the University of Maryland School of Pharmacy at 3:45-4PM on Monday entitled “Hepatic Micropatterned Co-Culture In Vitro Models for the Evaluation of DILI” discussing our #HEPATOPAC and #HEPATOMUNE models. Then check out our #ScientificPoster “Effective use of siRNA to assess low turnover compounds for reaction phenotyping in long term micropatterned hepatocyte co-culture HEPATOPAC®” presented by Devika Bhalerao on Tuesday morning. And watch the presentation “The Potential of Psychedelics for the Treatment of Neuropsychiatric Disorders” by Tina Mueller, PhD, at 9:15-10:15 AM on Wednesday. Learn more and view details: https://hubs.ly/Q03c3BTg0 #2025SOT #ADME #DMPK #Toxicology #Hepatocytes

Understanding #GenderBias and including representative #DiversityInResearch can help us understand the role of factors like: • Hormonal Influences • Genetic Predisposition • Environmental Triggers • Disease Heterogeneity • Population-Specific Risk Factors • Treatment Equity Similarly, using disease-state raw cellular starting materials offers a unique opportunity to advance effective #CellandGeneTherapy through: • Disease Modeling • Targeted Therapy Development • Understanding Disease Mechanisms Explore these concepts using #lupus and #autoimmune diseases as a case study in BioIVT’s newest blog post: https://lnkd.in/eDFmcEnQ #CellTherapy #GeneTherapy #AdvancedTherapies #ATMPs

Why settle for delays? BioIVT’s ready-to-ship human or animal #plasma and #serum are here—standardized volumes, rigorous QC, and timely delivery. With shorter lead times and easy online ordering, your research just got a whole lot more efficient. Don’t compromise on quality or convenience—discover the difference BioIVT can make for your research: https://lnkd.in/edXSKgmq #Biospecimens #DrugDiscovery #DrugDevelopment #Diagnostics #Bioanalysis

We’re pleased to announce our paper in collaboration with Jash Unadkat and Yik Pui (Tim) Tsang from UW has been published in Drug Metabolism and Disposition. Dr. Mark Warren, Senior Director at our Santa Clara lab, explained, “It describes our work testing numerous potential substrates against renal uptake and efflux transporters. Our own Nena Rodriguez and Tim Tsang from UW were able to identify selective substrates or substrate-inhibitor pairs for several of the key renal transporters. This knowledge will benefit our own work, as well as that of researchers studying drug interactions directly in kidney proximal tubule cells.” Access the article for free until April 20: https://hubs.ly/Q03b4pQr0 #DrugTransporters #DrugInteractions #ADME Elsevier

🧠 This #BrainAwareness Week, we're highlighting a critical issue in life science research: irreproducibility. Over 50% of preclinical studies fail to replicate, costing the U.S. $28 billion annually. One key reason? Many biospecimens labeled as "normal" lack proper cognitive screening. High-quality, well-characterized biospecimens are essential for reliable research and drug discovery. Our TruNormal® samples are rigorously tested with cognitive assessments, biomarkers, and medical history to ensure true physiological normalcy. Learn more about our matched sample solutions: https://lnkd.in/eZQkzXtq #BioIVTNeuroExcellence #Neuroscience #DrugDiscovery #Biospecimens